Chimeric Antigen Receptor News and Research

RSS

A Closer Look at CAR T-Cell Therapy — Successes, Challenges, And Future

Chimeric antigen receptor T-cell therapy enhances immune response against cancer, with promising results in hematological malignancies and ongoing advancements.

13 Nov 2024

Researchers Identify Mechanism of Immune Suppression in Ovarian Cancer

Researchers at Weill Cornell Medicine have shown that ovarian cancers disable immune cells and prevent them from attacking by cutting off the energy source that T cells rely on.

24 Oct 2024

CAR-NKT Cells Show Promise in Overcoming Solid Tumor Barriers

Chimeric antigen receptor T-cell therapy (CAR-T) has shown significant promise in the treatment of blood malignancies in the fight against cancer.

8 Oct 2024

UNC Researchers Unveil CAR-NKT Therapy for Enhanced Antitumor Activity

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors.

8 Oct 2024

CRISPR and Antibodies Offer New Hope for Improving CAR-T Cell Therapy Outcomes

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

13 Sep 2024

Metabolic Priming of CAR T Cells for Treatment of Solid Tumors

A promising therapy that treats blood cancers by harnessing the power of the immune system to target and destroy cancer cells could now treat solid tumors more efficiently.

3 Jul 2024

New Research Aims to Improve CAR-T Cell Therapy Effectiveness

CARISMa scientists at Goethe University Frankfurt introduced innovative CAR therapy that recognizes and specifically kills tumor cells. This cancer therapy is the focus of new federally funded LOEWE research.

1 Jul 2024

Targeting T Cell Metabolism to Boost Cancer Therapies

Recent findings from the lab of Jessica Thaxton, PhD, MsCR, in the UNC School of Medicine's Department of Cell Biology and Physiology, as well as associates in the Lineberger Comprehensive Cancer Center's Immunotherapy Group, have provided new insights into T-cell metabolism that may improve immunotherapies that depend on T cells to combat cancer.

18 Mar 2024

Asimov Launches LV Edge Packaging System to Optimize Lentivirus Production

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.

30 Jan 2024

Researchers Enhance CAR-T Cell Therapy by Preventing T-Cell Exhaustion

CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments such as chemotherapy are unsuccessful.

7 Nov 2023

Lactate Oxidase Nanocapsules Help the Immune System to Fight and Kill Solid Tumors

UCLA researchers have developed a new treatment method using a tiny nanocapsule to help boost the immune response, making it easier for the immune system to fight and kill solid tumors.

13 Oct 2023

Effectiveness of SCID-X1 Gene Therapy Influenced by 3D Genome Architecture

Patients with X-linked severe combined immunodeficiency disorder (SCID-X1), often known as “bubble boy disease,” are born with a faulty gene that inhibits immune cells from being produced.

9 Oct 2023

New CAR T Strategy Offers a Dual-Targeting Mechanism to Fight Bone Metastatic Prostate Cancer

Prostate cancer frequently metastasizes to the bone and is incurable. Moffitt Cancer Center researchers are working to identify new treatment options for this subset of patients.

4 May 2023

New Approach Could Power the Development of Advanced Cell Therapies

A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods.

2 May 2023

High-Throughput Assay to Analyze the Effects of CAR-T Cells Using Image Cytometry

The April 2023 issue of SLAS Discovery contains six full-length articles and one mini-review covering high-throughput screening (HTS) for protease-inhibiting drugs, high-content phenotypic screening and other life sciences research.

28 Apr 2023

New study pinpoints key source of T cell "exhaustion"

Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies.

21 Mar 2023

Gut microbiome may modulate the efficacy of CAR-T cell cancer immunotherapy

Scientists from German Cancer Research Center (DKFZ), together with colleagues from Germany, Israel, and the USA, have found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherapy CAR-T cells in patients with B cell lymphomas.

14 Mar 2023

Understanding the relationship between gut microbiome and CAR T-cell therapy response

Microorganisms live in or on almost every part of the human body and play an important role in the regulation of normal human processes. As a result, changes in the number or type of microorganisms, also known as the microbiome, can contribute to disease and altered responses to therapy, including cancer treatment.

14 Mar 2023

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.

15 Feb 2023

Treating ovarian cancer with immunotherapy involving CAR T cells

Recent research revealed that CAR T-cell therapy, a particular type of cancer treatment in which the immune system’s T cells are directed to kill tumor cells, is successful in treating ovarian cancer in mice.

7 Feb 2023